What the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.30%
Annual Rate
INR 1.25Paid unknown
Payout Ratio
15.9%Sustainable
Last Ex-Dividend
Jun 25, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
167.72BINR
1.76B · vs all stocks (USD)
Updated Jul 20, 2026
Trailing P/E
52.91x
vs Diagnostics & Research peers
Updated Jul 20, 2026
Revenue (TTM)
37.39BINR
391.82M · vs all stocks (USD)
Updated Jul 20, 2026
Profit Margin
8.47%
vs Diagnostics & Research peers
Updated Jul 20, 2026
Beta
-0.0010x
vs all stocks
Updated Jul 20, 2026
52-Week Change
-37.79%
vs all stocks
Updated Jul 20, 2026
Forward Annual Dividend Yield
0.30%
vs all stocks
Updated Jul 20, 2026
Market Capitalization
167.72BINR
1.76B · vs all stocks (USD)
Updated Jul 20, 2026
Enterprise Value
159.47BINR
1.67B · vs all stocks (USD)
Updated Jul 20, 2026
Trailing P/E
52.91x
vs Diagnostics & Research peers
Updated Jul 20, 2026
Forward P/E
33.29x
vs Diagnostics & Research peers
Updated Jul 20, 2026
PEG Ratio
4.22x
vs Diagnostics & Research peers
Updated Jul 20, 2026
Price to Sales (TTM)
4.49x
vs Diagnostics & Research peers
Updated Jul 20, 2026
Price to Book (MRQ)
3.47x
vs Diagnostics & Research peers
Updated Jul 20, 2026
Enterprise to Revenue
4.26x
vs Diagnostics & Research peers
Updated Jul 20, 2026
Enterprise to EBITDA
17.15x
vs Diagnostics & Research peers
Provider-reported. Enterprise Value ÷ EBITDA (TTM) on this page gives 14.03×.Updated Jul 20, 2026
Gross Margin
77.51%
vs Diagnostics & Research peers
Provider-reported. Gross Profit (TTM) ÷ Revenue (TTM) on this page gives 68%.Updated Jul 20, 2026
Profit Margin
8.47%
vs Diagnostics & Research peers
Updated Jul 20, 2026
Operating Margin
20.82%
vs Diagnostics & Research peers
Updated Jul 20, 2026
Return on Assets (TTM)
4.78%
vs Diagnostics & Research peers
Updated Jul 20, 2026
Return on Equity (TTM)
6.62%
vs Diagnostics & Research peers
Updated Jul 20, 2026
Revenue (TTM)
37.39BINR
391.82M · vs all stocks (USD)
Updated Jul 20, 2026
Revenue per Share (TTM)
92.94INRUpdated Jul 20, 2026
Quarterly Revenue Growth
1.80%
vs Diagnostics & Research peers
Updated Jul 20, 2026
Gross Profit (TTM)
25.42BINR
266.44M · vs all stocks (USD)
Updated Jul 20, 2026
EBITDA (TTM)
11.37BINR
119.14M · vs all stocks (USD)
Updated Jul 20, 2026
Net Income (TTM)
3.17BINR
33.19M · vs all stocks (USD)
Updated Jul 20, 2026
Quarterly Earnings Growth (YoY)
-19.30%
vs Diagnostics & Research peers
Updated Jul 20, 2026
Operating Cash Flow (TTM)
9.15BINR
95.91M · vs all stocks (USD)
Updated Jul 20, 2026
Levered Free Cash Flow (TTM)
7.28BINR
76.24M · vs all stocks (USD)
Updated Jul 20, 2026
Forward Annual Dividend Rate
1.25INRUpdated Jul 20, 2026
Forward Annual Dividend Yield
0.30%
vs all stocks
Updated Jul 20, 2026
Trailing Annual Dividend Rate
1.25INRUpdated Jul 20, 2026
Trailing Annual Dividend Yield
0.30%
vs all stocks
Updated Jul 20, 2026
Payout Ratio
15.88%
vs Diagnostics & Research peers
Updated Jul 20, 2026
Revenue
36.11BINRFY2026 · Mar 31, 2026
Cost of Goods Sold
9.19BINRFY2026 · Mar 31, 2026
Gross Profit
26.92BINRFY2026 · Mar 31, 2026
Operating Income
5.57BINR
58.41M · vs all stocks (USD)
FY2026 · Mar 31, 2026
Pre-tax Income
4.11BINRFY2026 · Mar 31, 2026
Income Tax Expense
942.00MINRFY2026 · Mar 31, 2026
Net Income
3.17BINRFY2026 · Mar 31, 2026
EBIT
4.56BINRFY2026 · Mar 31, 2026
EBITDA (Income Statement)
10.06BINRFY2026 · Mar 31, 2026
Selling, General & Administrative
2.05BINRFY2026 · Mar 31, 2026
Other Operating Expenses
4.89BINRFY2026 · Mar 31, 2026
Non-operating Interest Income
613.00MINRFY2026 · Mar 31, 2026
Non-operating Interest Expense
448.00MINRFY2026 · Mar 31, 2026
Net Income from Continuing Operations
3.17BINRFY2026 · Mar 31, 2026
Minority Interests (P&L)
0.00INRFY2026 · Mar 31, 2026
Preferred Stock Dividends
0.00INRFY2026 · Mar 31, 2026
Operating Cash Flow
1.84BINRFY2026 · Mar 31, 2026
Free Cash Flow
-1.60BINRFY2026 · Mar 31, 2026
Cash & Cash Equivalents (End of Period)
2.29BINRFY2026 · Mar 31, 2026
Starting Profit (CF Statement)
3.17BINRFY2026 · Mar 31, 2026
Stock-based Compensation
413.00MINRFY2026 · Mar 31, 2026
Other Non-cash Items
-114.00MINRFY2026 · Mar 31, 2026
Change in Accounts Receivable (CF)
-199.00MINRFY2026 · Mar 31, 2026
Change in Other Assets/Liabilities
-1.43BINRFY2026 · Mar 31, 2026
Capital Expenditures
-3.44BINRFY2026 · Mar 31, 2026
Net Intangibles (CF)
-242.00MINRFY2026 · Mar 31, 2026
Purchase of Investments
-34.60BINRFY2026 · Mar 31, 2026
Sale of Investments
29.17BINRFY2026 · Mar 31, 2026
Net Investing Cash Flow
-8.87BINRFY2026 · Mar 31, 2026
Long-term Debt Payments
0.00INRFY2026 · Mar 31, 2026
Net Short-term Debt Issuance
-996.00MINRFY2026 · Mar 31, 2026
Common Dividends Paid
-504.00MINRFY2026 · Mar 31, 2026
Net Financing Cash Flow
-1.50BINRFY2026 · Mar 31, 2026
Shares Outstanding
401.77MSharesUpdated Jul 20, 2026
Float Shares
175.40MSharesUpdated Jul 20, 2026
% Held by Insiders
52.80%
vs all stocks
Updated Jul 20, 2026
% Held by Institutions
38.16%
vs all stocks
Updated Jul 20, 2026
Total Cash (MRQ)
12.89BINR
135.10M · vs all stocks (USD)
Updated Jul 20, 2026
Total Cash per Share (MRQ)
32.08INRUpdated Jul 20, 2026
Total Debt (MRQ)
4.58BINR
48.04M · vs all stocks (USD)
Updated Jul 20, 2026
Total Debt to Equity (MRQ)
0.0947x
vs Diagnostics & Research peers
Updated Jul 20, 2026
Current Ratio (MRQ)
1.38x
vs Diagnostics & Research peers
Updated Jul 20, 2026
Book Value per Share (MRQ)
120.41INRUpdated Jul 20, 2026
Total Assets
70.55BINR
739.33M · vs all stocks (USD)
FY2026 · Mar 31, 2026
Total Current Assets
21.43BINRFY2026 · Mar 31, 2026
Total Liabilities
22.16BINRFY2026 · Mar 31, 2026
Total Non-current Assets
49.12BINRFY2026 · Mar 31, 2026
Total Non-current Liabilities
6.63BINRFY2026 · Mar 31, 2026
Total Current Liabilities
15.52BINRFY2026 · Mar 31, 2026
Cash
2.01BINRFY2026 · Mar 31, 2026
Cash Equivalents
280.00MINRFY2026 · Mar 31, 2026
Cash & Cash Equivalents
2.29BINRFY2026 · Mar 31, 2026
Other Short-term Investments
10.61BINRFY2026 · Mar 31, 2026
Accounts Receivable
5.09BINRFY2026 · Mar 31, 2026
Inventory
1.41BINRFY2026 · Mar 31, 2026
Accounts Payable
3.48BINRFY2026 · Mar 31, 2026
Short-term Debt
599.00MINRFY2026 · Mar 31, 2026
Other Current Liabilities
1.00MINRFY2026 · Mar 31, 2026
Long-term Debt
3.98BINRFY2026 · Mar 31, 2026
Other Non-current Liabilities
1.00MINRFY2026 · Mar 31, 2026
Common Stock (Book)
4.03BINRFY2026 · Mar 31, 2026
Retained Earnings
41.49BINRFY2026 · Mar 31, 2026
Total Shareholders' Equity
48.39BINR
507.13M · vs all stocks (USD)
FY2026 · Mar 31, 2026
Treasury Stock
53.00MINRFY2026 · Mar 31, 2026
52-Week Low
380.00INRUpdated Jul 20, 2026
52-Week High
728.60INRUpdated Jul 20, 2026
52-Week Change
-37.79%
vs all stocks
Updated Jul 20, 2026
Beta
-0.0010x
vs all stocks
Updated Jul 20, 2026
50-Day MA
444.76INRUpdated Jul 20, 2026
200-Day MA
512.19INRUpdated Jul 20, 2026
Avg 10-Day Volume
943.97KSharesUpdated Jul 20, 2026
Avg 30-Day Volume
996.28KSharesUpdated Jul 20, 2026
Diluted EPS (TTM)
7.89INRUpdated Jul 20, 2026
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.